2021
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)
Yardley DA, Young RR, Adelson KB, Silber AL, Najera JE, Daniel DB, Peacock N, Finney L, Hoekstra SJ, Shastry M, Hainsworth JD, Burris HA. A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC). Clinical Breast Cancer 2021, 22: 269-278. PMID: 34824002, DOI: 10.1016/j.clbc.2021.10.011.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerCohort 2Cohort 1Breast cancerAndrogen biosynthesisAmylase/lipaseLimited clinical activityPrior chemotherapy regimenPrior chemotherapy regimensMedian treatment durationNausea/vomitingChemotherapy regimenChemotherapy regimensPrimary endpointObjective responseOverall survivalFemale patientsAndrogen receptorClinical activityGrade 3Targetable pathwaysPatientsTherapeutic targetAR modulationTreatment durationPatterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Research 2021, 23: 14. PMID: 33514405, PMCID: PMC7844919, DOI: 10.1186/s13058-021-01394-y.Peer-Reviewed Original ResearchConceptsPrior endocrine therapyEndocrine therapyMetastatic breast cancerEffective treatment optionTreatment optionsBreast cancerMedian treatmentMedian OSEE therapyHormone receptor-positive HER2-negative metastatic breast cancerMultivariable Cox proportional hazards regression analysisHER2-negative metastatic breast cancerPrior treatmentCox proportional hazards regression analysisFirst-line therapy initiationProportional hazards regression analysisPrior treatment optionsLines of therapyProportion of patientsKaplan-Meier methodHazards regression analysisPatterns of treatmentElectronic health record-derived dataClinical trial dataOS benefit
2018
Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database
Chang E, Mougalian SS, Adelson KB, Young MR, Yu JB. Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database. Breast Cancer Research And Treatment 2018, 173: 209-216. PMID: 30242577, DOI: 10.1007/s10549-018-4968-7.Peer-Reviewed Original ResearchConceptsMetastatic-free intervalMetastatic breast cancerInitial breast cancer diagnosisBreast cancer-specific mortalityCancer-specific mortalitySubsequent metastatic diseaseBreast cancer diagnosisMetastatic diseaseFree intervalBreast cancerCancer diagnosisBreast cancer-specific survival ratesMetastatic breast cancer survivalCancer-specific survival ratesDiagnosis of MBCImproved cancer-specific survivalRecurrent metastatic breast cancerCancer-specific survivalEnd Results (SEER) databaseLow tumor gradeBreast cancer survivalChoice of treatmentStratification of patientsMethodsThe SurveillancePurposeThe prevalence
2016
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial
Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D. Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial. Npj Breast Cancer 2016, 2: 16037. PMID: 28721390, PMCID: PMC5515340, DOI: 10.1038/npjbcancer.2016.37.Peer-Reviewed Original ResearchProgression-free survivalSelective estrogen receptor downregulatorsMetastatic breast cancerER-positive metastatic breast cancerMedian progression-free survivalArm ABreast cancerArm BHormone receptor-positive metastatic breast cancerRandomized phase II trialPhase II trialEstrogen receptor downregulatorsProteasome inhibitor bortezomibPFS ratesII trialConsortium TrialHazard ratioPostmenopausal womenPreclinical modelsInhibitor bortezomibBortezomibCancerProteasome inhibitorsAdditional evaluationTrials
2011
OT3-01-01: Randomized Phase II Study of Fulvestrant Versus Fulvestrant Plus Bortezomib in Postmenopausal Women with Estrogen Receptor (ER) Positive, Aromatase-Inhibitor (AI) Resistant Metastatic Breast Cancer (MBC): New York Cancer Consortium Trial P8457.
Adelson K, Raptis G, Sparano J, Germain D. OT3-01-01: Randomized Phase II Study of Fulvestrant Versus Fulvestrant Plus Bortezomib in Postmenopausal Women with Estrogen Receptor (ER) Positive, Aromatase-Inhibitor (AI) Resistant Metastatic Breast Cancer (MBC): New York Cancer Consortium Trial P8457. Cancer Research 2011, 71: ot3-01-01-ot3-01-01. DOI: 10.1158/0008-5472.sabcs11-ot3-01-01.Peer-Reviewed Original ResearchMedian progression-free survivalMetastatic breast cancerProgression-free survivalAI therapyPostmenopausal womenMetastatic diseaseAI-resistant metastatic breast cancerResistant metastatic breast cancerAdjuvant AI therapyAI-resistant diseaseClinical benefit ratePrior chemotherapy regimenPhase II studyAdverse event ratesAddition of bortezomibHuman breast cancer cell linesEstrogen-receptor positiveRandomized phase II designsBreast cancer cell linesPhase II designUnfolded protein responseChemotherapy regimenEligible patientsMeasurable diseasePrior chemotherapy